The transaction is expected to strengthen Eurofins Transplant Diagnostics position in the pre- and post-transplantation organ testing market
Eurofins transplant diagnostics acquires HCTTL. (Credit: Adam Radosavljevic from Pixabay.)
Eurofins’ US Transplant Diagnostics has completed the acquisition of the Hawaii Cellular Therapy and Transplant Laboratory (HCTTL), to expand its footprint in the region.
HCTTL will merge with Eurofins VRL, a US-based pre-transplant testing firm, and expand its laboratories serving organ procurement organisations, tissue banks, and testing for donated biological materials.
Eurofins Transplant Diagnostics said that the transaction is in line with its expansion plans and strengthen and its position in the pre- and post-transplantation organ testing market.
University of Hawaii professor Randal K Wada said: “The laboratory plays a critical role in providing access to therapy by supporting the solid organ transplant program at The Queen’s Medical Center, as well as Legacy of Life Hawaii, the State’s organ and tissue donation program.
“We are thrilled that under Eurofins VRL, the laboratory will be able to take full advantage of state of the art technologies and be well-positioned to expand services and capacity in the future.”
Viracor is a 100% subsidiary of Eurofins Scientific, a provider of bio-analytical testing, and genomic services, through its diverse professional team experienced in testing, quality, regulatory, and customer service.
Viracor Eurofins has more than 30 years of expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients.
VRL-Eurofins is focused on performing donor eligibility screening and microbiology testing, using regulated testing technologies for the transplant and medical communities.
Furthermore, the firm operates eleven high complexity testing laboratories located in Colorado, Texas, Massachusetts, Georgia, California, Minneapolis, Pennsylvania, San Ramon, Cincinnati, Ohio, Winston-Salem, North Carolina and Hawaii.